	US 12,440,528 B2
	Methods of treating ovarian cancer with hemp extract
Alexandra M. Capano, Philadelphia, PA (US); Pradeep Singh Tanwar, Fletcher (AU); and Alex Nance, Georgetown, KY (US)
Assigned to Ecofibre USA Inc., Georgetown, KY (US); and The University of Newcastle, Callaghan (AU)
Filed by Ecofibre USA Inc., Georgetown, KY (US); and The University of Newcastle, Callaghan (AU)
Filed on Apr. 15, 2024, as Appl. No. 18/635,597.
Application 18/299,784 is a division of application No. 18/049,961, filed on Oct. 26, 2022, granted, now 11,654,171, issued on May 23, 2023.
Application 18/635,597 is a continuation of application No. 18/299,784, filed on Apr. 13, 2023, granted, now 11,975,036.
Claims priority of provisional application 63/263,018, filed on Oct. 26, 2021.
Claims priority of provisional application 63/263,026, filed on Oct. 26, 2021.
Claims priority of provisional application 63/263,020, filed on Oct. 26, 2021.
Prior Publication US 2024/0316133 A1, Sep. 26, 2024
Int. Cl. A61K 36/00 (2006.01); A61K 31/01 (2006.01); A61K 31/015 (2006.01); A61K 31/045 (2006.01); A61K 31/05 (2006.01); A61K 31/198 (2006.01); A61K 31/216 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/352 (2006.01); A61K 31/355 (2006.01); A61K 31/395 (2006.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61K 36/185 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)

CPC A61K 36/185 (2013.01) [A61K 31/01 (2013.01); A61K 31/015 (2013.01); A61K 31/045 (2013.01); A61K 31/05 (2013.01); A61K 31/198 (2013.01); A61K 31/216 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/352 (2013.01); A61K 31/355 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/5545 (2017.08); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)]

26 Claims

1. A method for treating ovarian cancer comprising:

a. administering to a patient an amount of a composition comprising a cannabis extract (CE) and a reduced amount of a chemotherapeutic agent as compared to a recommended amount of the chemotherapeutic agent;

b. wherein the chemotherapeutic agent is selected from the group consisting of: paclitaxel, altretamine, capecitabine, cyclosphosphamide, etoposide, gemcitabine, ifosfamide, itinotecan, doxorubicin, melphalan, pemetrexed, topotecan, binorelbine, carboplatin, cisplatin, docetaxel, and combinations thereof; and

c. wherein the composition comprising the cannabis extract comprises cannabidiol (CBD) at between 50% and 99% by weight of the CE and has a pH of between 3.5 and 6, said composition further comprising at least one additional cannabinoid present at between 0.1% and 10% by weight of the CE selected from the group consisting of:

Δ-9-tetrahydrocannabinol (Δ⁹-THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (48-THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.